Concepedia

Christy Osgood

CO

13

Publications

793

Citations

13

H-Index

2016

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Center for Devices and Radiological Health

Van Andel Institute

Christy Osgood is an author at Center for Drug Evaluation and Research specializing in radiation oncology, oncology, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2016–2024

13

Publications

13

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Preeti Narayan, Christy Osgood, Harpreet Singh et al. · Clinical Cancer Research · 2021 · 155 citations · Full text

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood et al. · Clinical Cancer Research · 2020 · 142 citations

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Mirat Shah, Christy Osgood, Anup Amatya et al. · Clinical Cancer Research · 2022 · 86 citations · Full text

Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor

Christy Osgood, Nichole Maloney, Christopher G. Kidd et al. · Clinical Cancer Research · 2016 · 71 citations · Full text

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective

Youwei Bi, Jun-Qiao Liu, Brian D. Furmanski et al. · Annals of Oncology · 2019 · 59 citations · Full text

Rows per page

1–5 of 13